Tonight the #gyncsm community discussed Gynecologic Cancer Research News presented at the SGO (Society of Gynecologic Oncology) and ASCO (American Society of Clinical Oncology) annual meetings. You may find our transcript here and analytics here.
Highlights from our chat:
T1: What #SGOmtg presentations/posters did you find most interesting?
- I attended #SGOmtg virtually this year and found a large number of studies focused on endometrial cancer and immunotherapies >> Combo’s like dostarlimab + chemo in the ENGOT-EN6-NSGO/GOG-3031/RUBY Trial showed improved OS
- One Recurrent OC study with Antibody drug conjugates (ADC)s the CDH6 directed Raludotatug deruxtecan (R-DXd) showed promising response in early studies Duration of response was 11 months #gyncsm #
T2: Which #ASCO24 studies do you think may be of most interest to patients?
- ASCO, one Trial for recurrent OC, AGO-OVAR 2.29 using Atezolizumab showed OS atezo arm 14.2 months vs 13.0 placebo arm, No better than without atezo , AE's higher in Atezo arm too. #ASCO24 #gyncsm
- ASCO published these notable studies for 2024 including: advanced epithelial ovarian cancer may safely avoid having their lymph nodes removed during cancer surgery without it impacting survival. https://society.asco.org/practice-patients/patient-resources/breaking-cancer-news-patients#CARACO
- T2 or this study People vaccinated for HPV have lower chances of developing HPV-related cancers, especially head and neck cancer in men and cervical cancer in women
- Use of biomarkers to target the best therapies to treat women with gyn cancer was talked about repeatedly at SGO.> Repair Assisted Damage Detection (RADD) as a potential predictive biomarker for immunotherapy response in ovarian cancer reported on by Dr Rocconi
- T3 Use of ctDNA was also a topic of interest at SGO and ASCO 1 study for cervical cancer Circulating #HPV 16/18 DNA detectable with 100% sensitivity in higher stage and 50% in low stage cervical cancer & at time of recurrence
T4: What are some of the "hot topics" in gynecologic cancer research currently? Will AI play a role?
- AI to predict homologous recombination deficiency in OC from histopathological images. #5578 deep neural networks (DNN), can provide a rapid/ scalable solution for HRD prediction, …model could significantly enhance efficiency, reduce the turnaround time and cost” #gyncsm
- T4 Machine learning used in a study cfDNA fragmentomics - New Classification test for endometrial ca, reported sensitive even for early stage cancer
- more emerging data and use in ongoing trials and practice in Her2 low endometrial with trastuzumab deruxtecan
- T4 It was good to see research for low grade serous OC treatments: MAPK assoc tumors better outcomes. Endocrine treatment studies, MEk inhibitors and CDK 4/6 inhibitors being researched. #gyncsm
T5: Once again, cancer drug shortages were highlighted at both #SGOmtg and #ASCO24. What resources for health care providers and patients are available?
- #ASCO24 video on Solving Decades of Drug Shortages in Oncology: What, Who, and When? Available at asco-meetings.gallery.video/2024-am-bonus- #gyncsm
- sgo.org/news/2023-fly-.@SGO_org Advocates and leaders worked hard on this ! #gyncsm
- Great resources here for management and how we can help raise awareness and support sgo.org/chemotherapy-d. #gyncsm
- T6 #ASCO24 Trends in palliative care utilization among patients with OC in the US. Use of inpatient PC for patients with OC increased over time, assoc wi/ older age, Black race, depression, and treatment in urban enviro or in teaching hospitals. #gyncsm
- T6 Cancer Cachexia - weight loss study dailynews.ascopubs.org/do/multipronge Combo of exercise , nutrition counseling ( omega 3 fatty acid use) and nonsteroidal anti-inflammatory medication prevented weight loss
— Nita Lee (@NitaKarnikLee) June 13, 2024
- #gyncsm #ASCO24 great session and discussion on rapid results availability on EMR and how best to balance better communication and expectations and pt preferences @TheLizArmy gave a great presentation on this! https://t.co/mlB9DIMwQM
Thanks to everyone who joined us. Remember you can continue our discussion about research on @smart_patients by joining Smart Patients at https://www.smartpatients.com/partners/gyncsm.
Our next Chat will be on September 11, 2024 at 8pm ET. See you then!
Dee and Christina
